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ABSTRACT
Neuroblastoma is a rare cancer of the sympathetic nervous system. A
neuroblastoma tumor develops in the nerve tissue and is diagnosed in infants and
children.1 Approximately 10.2 per million children under the age of 15 are affected in the
United States and is slightly more common in boys.1,2 Neuroblastoma constitutes 6% of
all childhood cancers and has a long-term survival rate of only 15%.2-4 There are
approximately 700 new cases of neuroblastoma each year in the United States. With
such a low rate of survival, the development of more effective treatment methods is
necessary.
A number of therapies are available for the treatment of these tumors; however,
clinicians and their patients face the challenges of systemic side effects and drug
resistance of the tumor cells. The application of nanoparticles has the potential to
provide a safer and more effective method of delivery drugs to tumors.5 The advantage of
using nanoparticles for drug delivery is the ability to specifically or passively target
tumors while reducing the harmful side effects of chemotherapeutics. Drug delivery via
nanoparticles can also allow for lower dosage requirements with controlled release of the
drugs, which can further reduce systemic toxicity.
The aim of this research was to develop a polymeric nanoparticle drug delivery
system for the treatment of high-risk neuroblastoma. Nanoparticles composed of a
poly(lactic acid)-poly(ethylene glycol) block copolymer were formulated to deliver a
non-toxic drug in combination with Temozolomide, a commonly used chemotherapeutic
drug for the treatment of neuroblastoma. The non-toxic drug acts as an inhibitor to the
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DNA-repair protein present in neuroblastoma cells that is responsible for inducing drug
resistance in the cells, which would potentially allow for enhanced temozolomide
activity.
A variety of studies were completed to prove the nanoparticles’ low toxicity,
loading abilities, and uptake into cells. Additionally, studies were performed to
determine the individual effect on cell toxicity of each drug and in combination. Finally,
nanoparticles were loaded with the non-toxic drug and delivered with free temozolomide
to determine the overall efficacy of the drugs in reducing neuroblastoma cell viability.
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CHAPTER 1
GENERAL INTRODUCTION
The research presented in this thesis focuses on the treatment of Neuroblastoma, a
rare cancer that affects the sympathetic nervous system. Neuroblastoma is a tumor that
develops in the nerve tissue and usually occurs in infants and children.1 It affects 10.2 per
million children under the age of 15 in the United States and is slightly more common in
boys.1, 2 It is the most common type of cancer to be diagnosed within the first year of life
(6% of all childhood cancers3) and has a long-term survival rate of only 15 percent.2,4
There are approximately 700 new cases of neuroblastoma each year in the United States,
and this number has remained roughly the same for several years.3 The application of
nanotechnology to develop safer and more effective systems for drug delivery has greatly
influenced the field of oncology and is a promising approach for the treatment of cancers
such as Neuroblastoma.5 An overview is provided outlining the etiology and progression
of neuroblastoma as well as the phenomenon of drug resistance is explained.
Additionally, an overview of Nanomedicine, the science behind nanoparticle drug
delivery and information about the specific drugs of interest is provided.
A literature review was performed to provide information on current treatment
approaches for neuroblastoma and research that has been conducted on nanoparticles as
drug delivery systems. The focus of this thesis remains on polymeric nanoparticles and
their capacity to be effective carriers for administering chemotherapeutic drugs. The use
of nanoparticles for drug delivery has the potential to significantly improve cancer
therapy while reducing the harmful side effects of chemotherapeutics.
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The goal of this research was to develop a novel drug delivery system for the
treatment of Neuroblastomas. The aim of this project was to overcome the drug resistance
of the cancer cells by encapsulating a non-toxic drug into polymeric nanoparticles that
can release the drug over a prolonged period of time combined with a free toxic drug.
This approach improves on the benefits of nanomedicine by passive or specific targeting
of tumors, and by mitigating the effects of drug resistance. The goal was to demonstrate
that co-administration of a non-toxic drug, O6-Benzylguanine with a toxic drug,
Temozolomide, lowered the drug resistance of a range of neuroblastoma cells thereby
lowering the concentration of toxic drug required and enhancing the efficacy of the drug
in eliminating the cancer cells. PLA-PEG- (OCH3) nanoparticles were synthesized and
drugs were encapsulated with interest for delivery to four different neuroblastoma cell
lines. Free drug studies were also performed to assess the effect of the drugs individually
as well as in combination to determine the optimal concentrations and time period needed
for effective treatment.
This paper provides an overview of current research as well as a detailed
methodology of the formulation of the polymeric nanoparticles and testing of the two
drugs on a panel of neuroblastoma cells.
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CHAPTER 2
NEUROBLASTOMA ETIOLOGY AND TREATMENT
2.1. Etiology
Neuroblastoma can develop in many areas of the body. It arises from the tissues
that form the sympathetic nervous system, which controls body functions such as heart
rate, blood pressure, digestion and certain hormone levels. This cancer starts in early
nerve cells known as sympathetic neuroblasts, and can be found anywhere in this
system.3 Neuroblastomas will most commonly begin in the abdomen, in the adrenal
glands, next to the spinal cord or in the chest. These neuroblastomas can spread to the
bones, bone marrow, liver, lymph nodes, skin and around the eyes. In most patients, the
neuroblastoma has already metastasized when it is diagnosed.1 It is a complex and
heterogeneous disease, and several factors such as age and stage of disease at diagnosis,
as well as molecular, cellular and genetic characteristics of the tumor determine whether
it will spontaneously regress or metastasize and become noncompliant to therapy. Sixty
percent of Neuroblastomas are metastatic and are mostly diagnosed after 18 months of
age.2 Clinicians typically use a 5-year survival rate to predict treatment success. This
refers to the percentage of patients who live at least five years after initial diagnosis of the
cancer. The national average for the 5-year survival time is 76.4%. The five-year
survival time in low-risk children is more than 90%, in children with intermediate risk is
70-90%, and only 30% in children with high-risk disease.5 The focus of the research and
experimental work presented in this thesis is on the treatment of high-risk neuroblastoma.
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As mentioned earlier, most neuroblastomas are found in the abdomen and
originate in the adrenal gland or sympathetic ganglia. Based on these common sites of
origin and cellular features of neuroblastomas, it is generally accepted that the cells
giving rise to neuroblastoma originate in the sympathoadrenal lineage of the neural crest
of development. The neural crest is present during embryogenesis and gives rise to
various cell types such as peripheral neurons, enteric neurons, glia, melanocytes,
Schwann cells and cells of the craniofacial skeleton and adrenal medulla. The adrenal
medulla is a ganglion of the sympathetic nervous system. Sixty-five percent of
neuroblastomas arise in the adrenal medulla and lumbar. A small percentage of patients
present a bilateral adrenal neuroblastoma suggesting that they may have a predisposing
genetic lesion indicating that the bilateral tumors arise from two independent genetic
lesions in the cells of the left and right sympathoadrenal lineage. It is also possible that
the initiating genetic lesion occurs during early development and the tumor-initiating
cells migrate bilaterally from the neural crest.2

Figure 1 | Development of the sympathoadrenal lineage of the neural crest3
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2.1.1. Familial Neuroblastoma
Children with the familial form of neuroblastoma are those with an inherited
tendency to develop this cancer, and usually come from families who had one or more
affected members as infants. Familial neuroblastomas are very rare, accounting for only
2% of neuroblastomas. The average age at diagnosis of familial cases is earlier than the
age for sporadic (not inherited) cases. Familial neuroblastomas are likely to develop
tumors in more than one organ rather than metastasizing, although metastases can occur
in either familial or sporadic forms.3 Familial neuroblastoma results from mutations in
some of the signaling pathways involved in the development of the sympathoadrenal
lineage. These mutations are associated with familial genetic syndromes characterized by
defects in development and predisposition to neuroblastoma. The first predisposition
mutation found in neuroblastoma was in paired-like homeobox 2b (PHOX2B), which
codes for a homeodomain transcription factor that promotes cell cycle exit, neuronal
differentiation, and has a key role in the development of neural crest-derived autonomic
neurons. Another, more common lesion related to familial neuroblastoma is in the
anaplastic lymphoma receptor tyrosine kinase (ALK) gene. ALK is expressed in the
developing sympathoadrenal lineage of the neural crest, where it is supposed to regulate
the balance between proliferation and differentiation via multiple cellular pathways,
including the MAPK and RAS-related protein 1 (RAP1) signal transduction pathways.
There is also evidence suggesting that PHOX2B can directly regulate ALK expression,
forming a connection between these two pathways that are mutated in familial
neuroblastoma. Although the ALK activating mutation F1147L contributes to
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neuroblastoma tumorogenesis in mice, this specific mutation has not yet been found in
familial neuroblastoma.2

2.1.2. Sporadic Neuroblastoma
Six to ten percent of sporadic neuroblastomas contain somatic ALK-activating
mutations, and 3-4% have a high frequency of ALK gene amplification. This
characteristic in both familial and sporadic neuroblastoma suggest that ALK is an
oncogenic catalyst in neuroblastoma, and activation of ALK mutations or amplifications,
especially in the presence of MYCN amplifications, are associated with fatal disease.
The most common focal genetic lesion in sporadic neuroblastoma is the amplification of
MYCN, occurring in approximately 22% of tumors. MYCN regulates proliferation,
growth, differentiation and survival of cells in the developing CNS. It is expressed in the
developing neural crest by several signaling pathways. Some neuroblastoma cells may
contain extra copies of the MYCN oncogene, which is an indication of fast tumor
progression and more difficulty in treatment.3 Even though MYCN is a major oncogenic
driver in neuroblastoma and has been studied extensively, there are no clinical trials
targeting the MYCN protein directly because of the inherent difficulties in developing
therapies that directly target transcription factors. Mutations in α-thalassaemia/mental
retardation syndrome X-linked (ATRX) are of the most common lesions in sporadic
neuroblastoma. It is suggested that ATRX functions in developmental processes, since
ATRX mutations are associated with X-linked mental retardation (XLMR), but little is
known about how ATRX contributes to the development or differentiation of the
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sympathoadrenal lineage. Children with XLMR do not have an increased incidence of
neuroblastoma, which indicates that ATRX mutations alone are not sufficient to promote
tumorigenesis.2 However, researchers have recently found that neuroblastoma cells in
older children are more likely to have mutations in ATRX. Tumors with this gene tend to
grow slowly, but are harder to eliminate.3
Cancer cells must maintain telomeres for survival, which in neuroblastoma, is
typically accomplished through increased expression on telomerase. High telomerase
activity is found in 30% of neuroblastomas at diagnosis and is indicative of reduced
event-free survival and overall survival in multivariate analyses.2
2.1.3. Heterogeneity of Neuroblastoma
The heterogeneity of neuroblastoma tends to influence the individual patient
response to therapy and prognosis. Heterogeneity among cancer cells in the same patient
can arise in multiple ways. The most established mechanism involves the intrinsic
differences among cancer cells caused by stochastic, genetic or epigenetic changes.
Differences can also result from extrinsic mechanisms in which different
microenvironments within a tumor present phenotypic and functional differences upon
cancer cells in different locations. Further, some cancers follow a stem cell model in
which tumorigenic cancer stem cells “differentiate” into non-tumorigenic cancer cells.
The cancer stem cell model is not a new development, and it has been known for decades
that some neuroblastomas can differentiate into a progeny that have limited proliferative
potential despite retaining the oncogenic mutations of their malignant progenitors. The
presence of only mature differentiated cells in residual tumor masses after chemotherapy
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is a positive prognostic factor, while the presence of residual undifferentiated cells
indicates disease recurrence.8 Neuroblastomas show varying degrees of differentiation.
Neuroblastomas with widespread differentiation generally have a better prognosis than
those with limited differentiation. Poorly differentiated neuroblastomas are usually
scattered and often fatal despite aggressive treatment. These observations have been
made clinically and suggest that undifferentiated neuroblastoma cells sometimes promote
disease progression.8

2.2. Current Research and Treatment Methods
The survival rate of all children diagnosed with high-risk neuroblastoma is less
than half after 5 years of diagnosis. With such a poor success rate, the development of
new agents and drug combinations is imperative to improving the prognosis for these
patients.6

By studying the tumor microenvironment, specific genes and proteins, and

mechanisms of drug resistance, a lot can be understood about developing safe and
effective treatment methods for neuroblastoma.
2.2.1. Current Research
Translational and clinical research for pediatric cancers is significantly different
from that of adult cancers because there are comparatively few patients and drug
metabolism, acute toxicities and late effects vary greatly between children and adults.2
Recent successes in the treatment of high-risk neuroblastoma may be attributed to the use
of higher doses of chemotherapy; some studies have credited the improvement to the use
of myeloablative doses of cytotoxic therapy in combination with autologous bone
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marrow transplantation. Relapse is common despite the achievement of remission, which
further suggests that minimal residual disease is an important cause of recurrence. Alltrans-retinoic acid (tretinoin) and 13-cis-retinoic acid (isotretinoin) decrease proliferation
and stimulate differentiation in neuroblastoma cells, and may be effective against residual
tumor cells that are resistant to cytotoxic agents.7 Among currently marketed treatments,
the delivery of anti-GD2 monoclonal antibodies has become the standard of care after
two decades of research, as a result of the discovery that high-risk patients with
neuroblastoma can maintain continuous remission with GD2-specific MAb therapy.2
GD2 belongs to a unique class of T cell-independent carbohydrate antigens. However,
the side effects of pain have restricted the anti-GD2 MAb dose and effectiveness has only
been shown in patients with minimal residual disease and has rarely been observed in
patients with bulky neuroblastoma. Early persistent minimal residual disease during
immunotherapy has been highly predictive of ultimate treatment failure. Currently
researched treatment strategies have been focused on immunotherapies such as vaccines
to stimulate T cell-mediated immunity and adoptive T-cell therapy. Chemotherapy is
common, and some children may receive neo-adjuvant chemotherapy (before surgery) or
adjuvant chemotherapy (after surgery). Most chemotherapy for neuroblastoma will
require a combination of drugs. The main drugs used include cyclophosphamide or
ifosfamide, cisplatin or carboplatin, vincristine, doxorubicin, etoposide, topotecan,
busulfan and melphalan.3 For children in the high-risk group, larger combinations are
used with higher doses, and may be followed by a stem cell transplant. The side effects
of chemotherapeutic drugs can be quite destructive and debilitating, especially for a child.
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For example, cyclophosphamide and ifosfamide can damage the bladder and affect
fertility; doxorubicin can cause heart damage; cisplatin and carboplatin can affect the
kidneys and vincristine may damage nerves.3 For this reason, we look towards
developing novel therapeutic methods such as delivering drugs via nanomaterials for
direct, targeted administration in order to avoid the systemic side-effects that accompany
treatment with a number of these commonly administered drugs.
2.2.2. Mechanisms of Cancer Drug Resistance
The ability of cancer cells to become resistant to a variety of drugs is known as
Multiple Drug Resistance (MDR). This phenomenon is a major challenge in treating
cancer because it inhibits the function of many chemotherapeutic drugs. MDR is
classified as either intrinsic or extrinsic. Intrinsic MDR occurs if the tumor cell is
inherently resistant to chemotherapy, and acquired MDR occurs if the tumor relapses
after treatment.9 MDR usually occurs because transporter proteins that expel drugs from
cells are over-expressed on the surface of cancer cells. The expulsion of drugs lowers the
therapeutic effect and cancer cells soon develop resistance to a variety of drugs.10 MDR
modulators are a group of drugs that can inhibit or reverse the processes that cause cancer
cells to become resistant. A significant reason to study nanomedicine to treat cancer is
because encapsulation of drugs in nanoparticles allows for co-administration of MDR
modulators with chemotherapeutics. Nanoparticle-mediated delivery of these drugs
lowers systemic toxicity and also evades ABC-transporter-mediated drug efflux.9
Additionally, in order to reduce cancer drug resistance for increased therapeutic
effectiveness, combination therapy has been widely adopted in clinics as a primary
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cancer treatment regimen. While applying multiple drugs with different molecular
targets can increase the genetic barriers that need to be overcome for cancer cell
mutations, it has also been demonstrated that multiple drugs targeting the same cellular
pathways could function synergistically for higher therapeutic efficacy and higher target
selectivity11
2.2.3. Role of O6-methylguanine DNA methyltransferase in Inducing Drug
Resistance
Alkylating agents are highly reactive molecules that bind to DNA and cause cell
death. The O6 position of guanine is the most frequent site of alkylation in DNA.
Alkylation at this site forms cross-links between adjacent DNA strands. The cellular
DNA-repair protein O6-methylguanine-DNA methyltransferase (MGMT) rapidly reverses
alkylation at the O6 position of guanine, thereby preventing the lethal cross-linking of the
double-stranded DNA. It is through this mechanism that MGMT causes resistance to
alkylating drugs.12–14 In the absence of MGMT, O6MeG in DNA generates point
mutations and DNA double-strand breaks via cellular replication and DNA mismatch
repair (MMR) that trigger cell death by apoptosis.37 It is known that MGMT is widely
expressed in all types of neuroblastoma and plays a key role in causing drug resistance in
the cancer. MGMT expression is primarily dependent on the methylation status of the
gene, that is, the presence of 5-methylcytosine in specific CpG islands of the mgmt
promotor. Regulation of MGMT expression is directed mainly via promotor methylation.
97 CpG islands have been identified in the mgmt promotor.37
Because of the significant impact MGMT has on cancer formation and therapy
effectiveness, it is well suited to be used as a biomarker. Therefore, there are specific
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methods for determining the MGMT levels of normal and cancerous tissues. These
methods include assays for MGMT activity, MGMT promoter methylation and MGMT
protein by immunohistochemistry (IHC). MGMT activity assays calculate the number of
active molecules per unit protein or DNA. This can be measured in homogenates from
fresh or frozen tumor tissue. This is expressed in fmol per mg protein, per µg DNA or
per cell number. MGMT activity corresponds with the MGMT protein and RNA level.
Another method is promoter methylation specific PCR (MSP), which is used to detect
promoter methylation. DNA methylation is a crucial mechanism for epigenetic gene
regulation and plays a significant role in carcinogenesis. Methylation of the CpG islands
of the mgmt promoter correlates with the loss of MGMT protein expression in tumor
tissue. Next, IHC allows determination of MGMT protein levels on sections from frozen
or paraffin embedded tumor tissue. Using specific antibodies and
colorimetric/fluorescent dyes to detect MGMT allows for semi-quantitative protein
assessment. Histological analysis can identify heterogeneous areas within a tumor and
distinguish tumor cells from non-neoplastic tissue. In a study conducted on methylation
mechanisms in primary colorectal cancers, it was shown that tumors containing a
methylated promoter show lower MGMT protein expression and activity than the nonmethylated tumors.37,38 MGMT status, as defined by activity, promoter methylation and
protein level, is currently regarded as a reasonable biomarker for predicting normal cell
response to alkylating carcinogens and the tumor’s response to O6-tumor-therapeutic
drugs.37
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There is high variability of MGMT activity between different tissues. Also, not
only does MGMT activity differ between different tissues, it also differs between
individuals and between different stages of development. In general, brain cancer has
low MGMT expression, which explains the relative sensitivity of nervous system cancers
to methylating anti-cancer drugs like TMZ.37 The comparison of MGMT activity in
normal and neoplastic human brain samples has been reported in various studies. In
general, the values for normal brain and primary brain tumors are similar and vary up to
40-fold in normal tissue and 100-fold for tumors. Due to the high levels of variation of
MGMT levels, it is possible that large changes in MGMT are associated with
tumorigenesis and that these changes affect response to treatment with alkylating agents.
For example, decrease in MGMT activity increases sensitivity to alkylating agents while
elevation of MGMT results in resistance to these agents. Silber et. al assayed MGMT
activity in 60 human brain tumors overlying 25 of these tumors with histologically
normal brain samples to determine whether MGMT content varied with diagnosis and
patient characteristics. Their results revealed large variation in MGMT content in
individual samples as well as in mean MGMT levels between specific tumor types.
Mean tumor and normal brain MGMT levels did not vary between males and females,
however MGMT levels in both neoplastic and normal tissue decreased with age. In
Silber’s experiment, the 60 tumor specimens were found to be highly heterogeneous in
MGMT content, with a range from <0.5-104.1 fmol/106 cells. Tumor MGMT was higher
in patients under 20 years of age than in those older than 20 years.33 In another study with
pediatric brain tumors, MGMT activity was found to be 5-fold higher in children between
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3 and 12 years than in infants and adolescents.37,39 Furthermore, a second study found 9fold higher MGMT activity in tumors versus normal brain.37 No strong correlation was
found between the fraction of cells in S phase and MGMT activity, suggesting that the
proliferative state of human brain tumors is not predictive of MGMT levels. Studies with
cultured cells have shown that proliferating cells have enhanced levels of DNA repair
activities. This, along with the finding that there is no correlation between the fraction of
tumor cells in S phase and MGMT activity, demonstrates that the inter-individual
variation of tumor MGMT activity is not due to differences in the fraction of proliferating
cells. Furthermore, it indicates that elevated MGMT levels accompanying tumorigenesis
is not a result of tumors containing greater numbers of proliferating cells than normal
brain.33
Repair mediated by MGMT is unique compared with other DNA repair pathways.
This is because MGMT repair (1) acts alone without relying on any other proteins or
cofactors; (2) transfers the alkyl group to an internal cysteine residue in the protein,
acting both as a transferase and an acceptor of the alkyl-group; (3) it inactivates itself
after receiving the alkyl-group from guanine, and is therefore a suicidal protein; (4) it
repairs in a stoichiometric fashion.34 The level of MGMT varies greatly according to the
type of tumor and also varies among same type of tumors. The MGMT gene is not
usually mutated or deleted, therefore a lack of MGMT may be caused by changes that do
not alter the genetic information of the cell. DNA methylation is the main type of
epigenetic modifications in humans, and plays an important role in tumorigenesis.12
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MGMT is a relatively stable protein, with a half-life greater than 24 hours. There is
evidence that phosphorylation of MGMT affects its activity.15,16
Repair by MGMT does not involve excision of the alkylated base from DNA; it is
a one-step reaction in which the methyl or chloroethyl group at the O6 position of guanine
is transferred to the cysteine residue in the active center of the MGMT molecule.16–18
This results in restoration of guanine in the DNA and irreversible inactivation of MGMT;
therefore, MGMT is often referred to as a “suicide enzyme.”16
Repair capacity is initially determined by the number of active MGMT molecules
in a cell and, if damage levels exceed the levels of pre-existing molecules, the rate of de
novo synthesis following inactivation. Protection against cell death is a linear function of
MGMT activity up to MGMT levels of approximately 200,000 molecules per cell, above
which the toxicity of other lesions becomes dominant. Some evidence suggests that after
alkyl group transfer, MGMT undergoes ubiquitination and proteosome-mediated
degradation.16
No other functions of MGMT have been described. In adherent cells, no effect on
cell growth is observed whether they express low or high levels of MGMT. This
indicates that MGMT is not linked to regulation of proliferation. Additionally, although
MGMT is often up-regulated in cells of more aggressive tumors, there is no evidence that
MGMT has a direct stimulator or inhibitory effect on tumor growth.16 Interestingly
enough, however, a compilation of data exhibits that the normal brain tissue of brain
tumor patients shows lower MGMT activity than that of non-tumor patients. This finding
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suggests that individuals with low MGMT activity in the brain are more prone to brain
tumor formation.37, 39
Only limited data is available comparing MGMT expression, activity and clinical
outcome. In one study with newly diagnosed or recurrent glioma, 24% of tumors lacked
detectable MGMT activity. In another study comparing the clinical outcome of
combined radiotherapy/TMZ therapy in glioblastoma patients expressing low and high
MGMT activities, there was a better therapeutic response when the pretreatment tumor
expressed below 30 fmol/mg protein activity compared to patients expressing MGMT
above this point.37
2.2.4. Application of O6-Benzylguanine for Inhibition of MGMT
Recent research indicates that it may be possible to increase the sensitivity of
resistant tumors with the use of agents that inhibit MGMT. One such inhibitor is O6benzylguanine (O6-BG); it is a substrate for MGMT that inactivates the enzyme. O6-BG
has been shown to enhance the response to alkyl nitrosoureas in vitro and in vivo.12 O6BG reacts with MGMT by covalently transferring the benzyl group to the active site,
cysteine, and causes an irreversible inactivation of the enzyme. Alone, O6-BG is not
toxic, but it induces tumor cells to be 2- to 14-fold more sensitive to alkylating agents in
the in vitro and in vivo settings. This establishes the potential of O6-BG as a therapeutic
enhancer of these drugs.34 Complete inactivation of MGMT activity was observed as
early as 15 minutes after addition of O6-BG to culture medium.16,19 O6-BG has remained
the most extensively used agent for experimental purposes and in pre-clinical and clinical
trials due to its promising properties. In initial pre-clinical experiments, pre-treatment

	
  

	
  
16	
  

with O6-BG increased carmustine sensitivity in athymic mice bearing either human
medulloblastoma or human glioblastoma xenografts, showing regression of 18/20
xenografts. In recent phase I clinical trials, it was determined that in adult patients, O6BG doses of 100 mg/m2 to 120 mg/m2 are necessary for complete inactivation of
MGMT.16,20,21 Furthermore, the maximal dose of TMZ was found to be 470 mg/m2, given
with this dose of O6-BG.34 In phase I trials with O6-BG in children suffering from CNS
tumors, the maximal tolerated dose of TMZ given 30 minutes after infusion of 120
mg/m2/day O6-BG for 5 consecutive days was 100 mg/m2/day.16,22 Antitumor activity
was observed at 120 mg/m2/day O6-BG combined with TMZ doses greater than 55
mg/m2/day.17 These results are promising indicators for the CNS tumor models tested,
which suggest that the combination treatment of Temozolomide and O6-Benzylaguanine
on neuroblastoma tumor models should show similar results.
2.2.5. Treatment of Neuroblastoma with Temozolomide and O6-Benzylguanine
Temozolomide (TMZ) is a new generation drug, commercially known as
Temodal, or Temodar® .17 It is DNA methylating imidazole tetrazinone that inhibits cell
growth in neuroblastoma.23 This drug does not need metabolic activation and decomposes
spontaneously into its active form, methyltriazenoimidazole carboxamide (MITC), which
releases carbonium ions that alkylate DNA. It has recently been shown that apoptosis
occurs in the 2nd, 3rd and 4th cell cycle following treatment with TMZ.17 Phase I studies in
adults and children determined the maximum tolerated dose as 200 mg/m2/d for five
days. Myelosuppression is the dose-limiting toxicity of TMZ and other O6-alkylating
drugs. For TMZ, myelosuppression occurred at a total dose of 1.25 g/m2 and was
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reversible and noncumulative. According to recent studies, continuous TMZ
administration allows dose escalation from 1,000 to 2,100 mg/m2 over 28 days and
causes prolonged MGMT depletion, but such clinical studies have not been conducted yet
on children.24 It was shown that 7% of patients had grade 3 or 4 hematological toxic
effects following concomitant radiotherapy and TMZ, and 14% following adjuvant
TMZ.17 The cytotoxic activity of TMZ is mediated through reactive O6-methylguanine in
DNA, therefore, inhibition of MGMT may increase the cytotoxicity of TMZ against
neuroblastomas.25
The high level of MGMT expression is one recognized mechanism of TMZ
resistance. This DNA repair protein removes methyl adducts placed on DNA by TMZ,
thereby reversing the cytotoxic effects of the drug.6 The mechanism of the toxic effect of
O6-alkylating agent, in the majority of situations, suggests that repair by MGMT almost
completely inhibits cell death, particularly in the lower dose range of the agents.17
Sensitivity to TMZ appears to be inversely related to levels of MGMT expression, which
can be quantified directly at the protein level by immunohistochemistry analysis of tumor
tissue, or indirectly by assessing methylation of the promoter that regulates MGMT
expression because hypermethylation silences the expression of this gene. It has been
shown that patients whose tumors express high levels of MGMT would fail TMZ
therapy.6 In glioma cells in vitro, MGMT is recovered within 1-2 cell cycles following a
single TMZ treatment, but this effect will be dose and cell line dependent.17
Another known mechanism of resistance to TMZ is decreased or nonexistent
expression of the mismatch repair proteins MSH-2 and MLH-1. In the presence of
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methylating agents such as TMZ, it is theorized that these repair enzymes engage in
recurring attempts to repair DNA lesions, generating a chronic strand break condition that
induces apoptosis. Therefore, the presence of an intact mismatch repair system seems to
be necessary for TMZ cytotoxicity. However, reports indicate that this mechanism of
resistance is uncommon in neuroblastoma.7
Given the availability of the MGMT-inactivating agent, O6-Benzylguanine (O6BG), MGMT could be a relevant therapeutic target due to its wide expression in
neuroblastoma. O6-BG has been shown in single-agent clinical studies to effectively
inactivate MGMT activity in tumor tissue. Further, in pre-clinical experiments, pretreatment with O6-BG significantly improved the activity of TMZ against various tumors
with a range of MGMT activity as a result of depleting MGMT protein.7 Pre-treatment
with O6-BG (35 mg/kg) completely eliminated MGMT activity in mice bearing human
melanoma xenografts, and the combination of TMZ (40 mg/kg) administered together
with O6-BG on five consecutive days produced a significant tumor growth delay in
comparison to TMZ alone.16 Phase II trials are currently in progress in adults and
children with brain tumors to evaluate the clinical activity of O6-BG combined with
TMZ.7 In the case of metastatic neuroblastoma xenografts, combined TMZ/Irinotecan
(IRN) therapy with O6-BG enhanced the survival of mice by from 10% to 56%. 7,17 This
drug has been clinically shown to effectively inactivate MGMT activity in tumor tissue.
Friedman et al. observed the drug combination of O6-BG-TMZ-IRN in a murine model of
malignant glioma expressing MGMT. They found that the three-drug combination
delayed tumor growth by a median of >150 days compared to <37 days for each drug
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alone. Based on this data, tumors with higher sensitivity to TMZ would express little
MGMT but retain MLH-1 and MSH-2. In tumors with high MGMT expression coupled
with a mismatch repair system, pre-treatment with O6-BG should increase sensitization to
TMZ.7
In an in vitro study conducted by Wagner et. al, MGMT expression was detected
in 88% of neuroblastoma tumor samples by immunohistochemistry. There was variation
of >40% in only 6 (8%) of the tumors, which is likely related to the heterogeneous
expression of MGMT within a single tumor. There was no correlation between disease
stage and level of MGMT expression. It was concluded that the majority of primary
neuroblastoma cell lines express MLH-1, MSH-2 and MGMT. These results indicated
that expression of MGMT might be the more common mechanism of resistance to TMZ
in neuroblastoma cells.7
In an assessment of the effect of O6-BG on the sensitivity of neuroblastoma cell
lines to TMZ, 25 µmol/L of O6-BG, which has previously been shown to inactivate
MGMT, was added to the cell cultures 24 hours prior to addition of varying
concentrations of TMZ. The data showed that O6-BG sensitized the cells to TMZ by 11to 12-fold. It was also demonstrated that O6-BG reduced the IC50 of TMZ by
approximately 10-fold.7
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CHAPTER 3
POLYMERIC NANOPARTICLES AND APPLICATION TO CANCER TREATMENT
3.1 Nanotechnology and Nanomedicine
Nanotechnology is defined as the understanding and control of matter in the 1-100
nm dimension range. Nanomedicine is the application of nanotechnology to medicine,
and involves the use of engineered materials at this scale to develop novel therapeutic and
diagnostic modalities. The use of nanomaterials provides the ability to modify properties
such as solubility, diffusivity, blood circulation half-life, drug release characteristics, and
immunogenicity. The last two decades have seen a rapid growth in the development of
nanoparticle-based therapeutic and diagnostic agents for the treatment of cancer, diabetes,
pain, asthma, allergy, infections, etc. These nanomaterials may provide more effective
and convenient routes of administration, lower therapeutic toxicity and eventually reduce
health-care costs. Nanoparticles allow targeted delivery and controlled release as
therapeutic delivery systems.26 Commonly recognized nanoparticle vectors include:
liposomes, micelles, dendrimers, solid lipid nanoparticles, metallic nanoparticles,
semiconductor nanoparticles, and polymeric nanoparticles.9 There are many advantages
of nanoparticle-based drug delivery systems; these include: (1) the ability to improve the
solubility of poorly water-soluble drugs, (2) prolonged half-life of drug systemic
circulation by reducing immunogenicity, (3) sustained release of drugs thereby lowering
frequency of administration, (4) delivery of drugs in a target manner to minimize
systemic side effects, (5) delivery of two or more drugs simultaneously for combination
therapy for increased efficacy, and (6) delivery of drugs across a range of biological
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barriers including epithelial and endothelial. Additional advantages of nanoparticles
include specific binding of drugs to targets in cancer cells, visualization of tumors using
various imaging modalities, and optimized dose scheduling for improved patient
compliance.27 More than 20 nanoparticle therapeutics have been approved by the FDA
for clinical use and numerous nanoparticle products are currently under clinical testing
for various applications.26-28
3.2 Nanoparticles for Cancer Treatment
The search for a successful cancer treatment depends on the discovery of the
ultimate therapeutic and delivery method. Traditional treatment options such as
chemotherapy and radiation have made significant advances over the past decades,
however, cancer therapy is still not completely optimized. The effectiveness of cancer
therapy depends on a fine line between the ability of the therapeutic to eliminate the
tumor while minimizing the negative affect on healthy cells. Systemic administration of
bolus doses of powerful chemotherapeutics often results in severe side effects due to the
action of the drugs on sites other than the intended target. With this nonspecific drug
action, the concentration of the drug that can be available at the tumor site itself may be
below the minimal effective concentration, resulting in a difficult dilemma between
choosing a near-toxic effective dose and a comfortable ineffective dose. Further,
intravenous injection of toxic agents introduces a serious threat to healthy tissues and
leads to dose-limiting side effects.11 As a result, decades of research have focused on
developing cancer-specific drugs and delivery systems that can preferentially localize
therapeutic agents to the tumor site.9
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Nanoparticles are effective tumor-targeting vehicles because of the unique innate
property of solid tumors. Solid tumors undergo rapid growth and as a result typically
have fenestrated vasculature and poor lymphatic drainage, causing an enhanced
permeability and retention (EPR) effect.27 Rapid and defective angiogenesis causes
increased permeability of the blood vessels in tumors.10 This property allows
nanoparticles to accumulate specifically at the tumor site. Blood vessels in tumors are
irregular in their structure compared to those in normal tissues. Tumor vessels are
heterogeneous in their distribution, dilated and tortuous, and leave avascular spaces of
varying sizes. The tumor vessel-wall structure is characterized by wide inter-endothelial
junctions, an abnormally thick or thin basement membrane, leakiness and hyperpermeability in some areas and maximum pore diameters of several hundred
nanometers.27
The elevated viscous and geometrical resistance of the vasculature can
compromise tumor blood flow. As a result, the average velocity of red blood cells
(RBCs) in tumor vessels can be significantly lower than in normal vessels and the overall
perfusion rates in tumors are also lower compared with normal tissues. Blood velocity in
tumors is independent of vessel diameter and unevenly distributed, creating poorly
perfused or un-perfused regions. The presence of these un-perfused regions results in a
hostile tumor microenvironment, which is characterized by low partial oxygen pressure,
low pH and necrotic tissue, which contributes to drug resistance and tumor progression.
Furthermore, functional lymphatic vessels only exist in the tumor periphery. These
peritumor lymphatics transport fluid, growth factors, cancer cells, and mediate tumor
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metastases via the lymphatic network. The inefficiency of fluid drainage from the tumor
center along with fluid leakage from tumor vessels contributes to interstitial
hypertension.27 Consequently, the dysfunctional lymphatic drainage in tumors retains the
accumulated nanoparticles and allows them to release drugs in the vicinity of the tumor
cells.11 Nanoparticles protect the drug from rapid metabolism and clearance, as well as
preventing uptake by the reticuloendothelial system and mononuclear macrophages.
Nanoparticles thus have the ability to circulate for prolonged periods of time, allowing
them to eventually reach the tumor vasculature where, with the aid of the EPR effect,
they specifically extravasate through the fenestrated capillaries to accumulate drugs at the
tumor mass. Further, at the tumor site, nanoparticles can be endocytosed/phagocytosed
therefore enhancing cell internalization of the drug and leading to delivery of the drug
closer to the intracellular site of action.9 Transport of a therapeutic agent from the
systemic circulation to cancer cells is a three-step process: First, nanoparticles flow to
different regions of tumors via blood vessels. Then, they must cross the vessel wall, and
finally, penetrate through the interstitial space to reach the target cells. The elevated
interstitial fluid pressure (IFP) resulting from the interstitial hypertension reduces
convective transport, while the dense extracellular matrix hinders diffusion. This brings a
challenge to delivering drug-loaded nanoparticles because this interstitial hypertension
and defective blood supply reduces the efficacy and delivery of the therapeutic agents to
solid tumors. Subsequently, hypoxia in tumor cells induces resistance to chemotherapy
as well as resistance to several cytotoxic drugs. As a result, strategies to enhance drug
delivery have focused on normalizing the tumor vasculature to increase the efficiency of
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the vascular network, and normalizing the tumor interstitial matrix, so that nanoparticles
penetrate faster and deeper inside the tumor. For optimal efficiency, the therapeutic
agent must reach tumors in sufficient amounts to kill cancer cells but at the same time not
adversely affect normal tissues. In this case, the smaller the particles the better the
transport, however, small molecules such as chemotherapeutics generally extravasate in
normal tissues, which may cause adverse effects. The size of the particles also affects
their circulation time in the blood stream; as long as the therapeutic agent is not toxic to
normal tissues, it makes sense to prolong its half-life in the blood. Therefore, the size of
the particle must be optimized for each tumor and its metastases.27 In addition to size, the
surface charge of the nanoparticle also plays a crucial role in extravasation and interstitial
transport. Cationic nanoparticles have been shown to preferentially target tumor
endothelial cells and exhibit higher vascular permeability than their neutral or anionic
counterparts. Neutral nanoparticles diffuse faster and distribute more homogeneously
inside the tumor interstitial space than cationic and anionic particles, because the latter
form aggregates with negatively or positively charged molecules. Transport of
nanoparticles through the interstitial matrix is governed by diffusion and convection, as
shown in the equation below:

Figure 2 | Mathematical model describing transport of nanoparticles through the
interstitial matrix.27
Where Ci is the nanoparticle concentration, v the interstitial fluid velocity, D the diffusion
coefficient of the nanoparticles and R that accounts for binding or degradation of the
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nanoparticles. The fluid velocity depends on changes in the interstitial fluid pressure and
the diffusion coefficient depends on the nanoparticle properties (size, charge,
configuration) and the structure of the interstitial matrix.27
3.3 Polymeric Nanoparticles
It has been shown that nanoparticle and polymer conjugate delivery can allow
concentrations of the drug near the tumor site to reach 10- to 100-fold higher than when
administering free drug.9 As a result, many of the nanoparticle therapeutics currently in
clinical and preclinical investigations are polymeric nanoparticles. Polymeric
nanoparticles are engineered from biocompatible and biodegradable polymers. Most of
these nanoparticles are formulated using block-copolymers consisting of two or more
polymer chains with different hydrophilicity. These copolymers spontaneously assemble
into a core-shell structure in an aqueous environment. The hydrophobic blocks form the
core to minimize the exposure to aqueous surroundings while the hydrophilic blocks form
the shell to stabilize the core. This creates a structure that is well suited for drug delivery.
The hydrophobic core can carry therapeutics with high loading capacity while the
hydrophilic shell provides steric protection for the nanoparticle.28 Polymeric
nanoparticles are identified by their morphology and polymer composition in the core and
corona.36
The therapeutic load can be conjugated to the surface or encapsulated inside the
core.36 Polymeric nanoparticles can be formulated to encapsulate either hydrophilic or
hydrophobic small drug molecules. These structures have a diameter typically ranging
from 10 to 100 nm.29 The drug delivery systems can be designed to deliver controlled
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release or a triggered release of the therapeutic. The most important characteristics of
nanoparticles are their size, encapsulation efficiency, zeta potential, and release
characteristics. Nanoparticles have an advantage over larger microparticles because they
are better suited for intravenous delivery. The smallest capillaries in the body are 5-6 µm
in diameter; consequently, the size of particles being circulated in the bloodstream must
be significantly smaller than 5 µm, without forming aggregates to ensure that the particles
do not form an embolism.7
The most commonly used polymers for nanoparticles are poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and poly(lactide-co-glycolide) (PLGA). These polymers are
known for their biocompatibility and resorbability through natural mechanisms8.
Polyethylene glycol (PEG) has also been widely used to enhance the pharmacokinetics of
nanoparticle formulations. PEG is a highly hydrated flexible polymer chain that limits
plasma protein adsorption and biofueling of nanoparticles while reducing renal clearance
of relatively smaller drug molecules, thereby prolonging drug circulation half-life. PEG
is also non-toxic and non-immunogenic, which makes it appropriate for clinical
applications.7 In fact, PLA-PEG and PLGA-PEG nanoparticles for delivery of anticancer
drugs have been approved outside the United States and are in late-phase clinical trials
within the United States.30 Natural polymers such as proteins or polysaccharides have not
been widely used for the purpose of nanoparticle drug delivery since they vary in purity
and often require cross-linking which could denature the embedded drug. Many protocols
exist for synthesizing nanoparticles based on the type of drug used and the desired
delivery route. Once a protocol is chosen, the parameters must be adjusted to create the
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best characteristics for the nanoparticles.7 The most common method for preparation of
solid, polymeric nanoparticles is the emulsification-solvent evaporation technique, a
method that is effective for encapsulating hydrophobic drugs.8 PLA-PEG is an
amphiphilic polymer that s flexible in solution and it contains free amino and carboxyl
groups that ionize and interact in water. These characteristics allow it to self-assemble
and encapsulate chemicals via hydrophobic/hydrophilic and electrostatic interactions.31
The chain length, shape and density of PEG on the particle surface have been considered
to be the main parameters affecting nanoparticle surface hydrophilicity and
phagocytosis.36 The primary reason for preparing PEG functionalized particles is to
improve the long-term systemic circulation of the nanoparticles. PEG functionalized
particles are not recognized as foreign bodies and are not taken up by the body, allowing
them to circulate longer providing for a sustained systemic drug release. Due to this
behavior, and their ability to prevent protein absorption, PEG functionalized
nanoparticles are often called “stealth nanoparticles.”36,7
There are numerous known barriers that exist in the human body to protect it from
foreign particles. These barriers include cellular and humoral branches of the immune
system as well as mucosal barriers. Nanoparticles are well suited to overcome these
barriers to reach their target due to their unique size, and ability to accept surface
functionalization to incorporate desired characteristics.36 The next phase of research in
nanoparticle systems involves the addition of targeting ligands such as antibodies,
peptides, and aptamers, which may further improve efficiency and reduce toxicity.26
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3.4 Drug Encapsulation & Release Characteristics
Drug loading into polymeric nanoparticles can be achieved by three techniques:
(1) the drug is covalently attached to the polymer backbone, (2) the drug is adsorbed to
the polymer surface, or, (3) the drug is entrapped in the polymer matrix during
preparation of the nanopartices.32 In the latter method, drug encapsulation is achieved by
mixing the drug with the polymer solutions during a solvent displacement technique. A
water-miscible solvent such as acetonitrile is used to dissolve the hydrophobic drugs
together with the di-block copolymers. The solution is mixed with water. The organic
solvent diffuses into the aqueous phases and evaporates, and the hydrophobic polymers
self assemble to form nanoparticles with drugs encapsulated inside.11 The molecular
weight and concentration of the polymer used affects the nanoparticles. The molecular
weight of the polymer has opposite effects on nanoparticle size and encapsulation
efficiency. Smaller nanoparticles can be prepared with lower molecular weight polymer,
however, resulting in reduced drug encapsulation efficiency. Conversely, a higher
polymer concentration increases encapsulation efficiency and size of nanoparticles.8 As
emphasized earlier, particle size and encapsulation efficiency are two of the most
important characteristics of nanoparticles for drug delivery applications. It is necessary
to determine what the goal of the nanoparticle delivery system is before deciding on the
desired size. For example, if the goal is rapid dissolution in the body then the particle
size should be approximately 100 nm or less. If prolonged dissolution is desired, larger
particles around 800 nm are preferred. That said, encapsulation efficiency increases with
the diameter of the nanoparticles.7
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Several factors affect the release rate of the entrapped drug. Larger particles have
a smaller initial burst release and longer sustained release than smaller particles.
Additionally, greater drug loading leads to greater burst and faster release rate.11 For
example, in a study conducted by Leroux et. al, PLA nanoparticles containing 16.7%
savoxepine released 90% of their drug load, while particles containing 7.1% savoxepine
released their content over 3 weeks. The initial burst release is believed to be caused by
poorly entrapped drug, or drug adsorbed onto the outside of the particles.7 Polymeric
nanoparticle drug delivery systems are relatively stable in vivo, and can employ both
controlled or triggered release of drugs.11
Compared to other nanomaterials, polymeric nanoparticles have higher stability,
sharper size distribution, more tunable physicochemical properties, sustained and more
controllable drug-release profiles, and higher loading capacity for poorly water-soluble
drugs.11 As a result of these properties, PEG-PLA nanoparticles are suitable carriers for
therapeutics to (1) minimize the drug resistance of the cancer cells and (2) allow for
effective treatment of the cancer by the specific drug of interest. This forms the basis of
the experimental work presented in this thesis.
CHAPTER 4
FORMULATION AND DELIVERY OF O6-BENZYLGUANINE LOADED PLA-PEG(OCH3) NANOPARTICLES I2N COMBINATION WITH TEMOZOLOMIDE
4.1 Introduction
The goal of this research was to develop a polymeric nanoparticle drug delivery
system for the treatment of high-risk neuroblastoma. In order to enhance the efficacy of
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the therapeutic drug Temozolomide, it was necessary to overcome the drug resistance of
the neuroblastoma cells by inhibition of MGMT. To develop this drug delivery system,
PLA-PEG-(OCH3) nanoparticles were synthesized and encapsulated with the non-toxic
MGMT inhibiting agent, O6-Benzylguanine. These drug-loaded nanoparticles were coadministered with the toxic therapeutic Temozolomide (TMZ). Concentrations of TMZ
were varied while keeping nanoparticle and O6-BG concentrations constant and
incubation periods of 24, 48 and 72-hours were tested.
To prove that the O6-BG loaded nanoparticles and the nanoparticles themselves
were non-toxic, the cells were also treated with drug-loaded and unloaded nanoparticles.
PLA-PEG-(OCH3) nanoparticles were synthesized and delivered to cells at varying
concentrations and incubation periods of 24, 48 and 72-hours. O6-BG was loaded into
the nanoparticles at 2 mg/mL. Nanoparticle concentration was varied to determine the
optimal concentration that can be administered without causing toxicity.
It was also necessary to test the effect of the individual drugs on cell viability.
Free O6-BG, free TMZ and combination free O6-BG + TMZ toxicity studies were
conducted. 3 types of free drug combination studies were conducted to vary the
concentrations of both drugs, either holding TMZ constant and varying O6-BG or holding
O6-BG constant and varying TMZ. The results of these studies were used to determine
the optimal concentration of each drug that did not exceed desired toxicity levels. These
optimal concentrations were later used to determine the drug concentrations needed for
drug-nanoparticle combination studies.
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Lastly, to confirm that the nanoparticles were indeed uptaken by the cells, a
fluorescent NP uptake study was performed. Alexa Fluor 647 cadaverine was conjugated
with PLA to formulate a fluorescent polymer. This polymer was then conjugated with
PLA-PEG-(OCH3) and fluorescently tagged nanoparticles were synthesized. These
nanoparticles were delivered to the neuroblastoma cells and uptake was measured by
imaging the cells using IVIS after individual incubation periods of 1, 24, 48 and 72-hours
4.2 Materials
For the synthesis of PLA-PEG-(OCH3), D,L lactide (C6H8O4, PURASORB DL)
was supplied by Purac Biomaterials. Tin (II) 2-ethylhexanoate
([CH3(CH2)3CH(C2H5)CO2]2-‐	
  -‐Sn,	
  ~95%),	
  sodium	
  sulfate	
  (Na2SO4,,	
  >99%),	
  anhydrous	
  
magnesium	
  sulfate	
  (MgSO4,	
  >99.5%),	
  anhydrous	
  toluene	
  (C6H5CH3,	
  99.8%),	
  
methanol	
  (CH3OH,	
  >99.9%),	
  and	
  chloroform	
  (CHCl3,	
  >99.8%)	
  were	
  supplied	
  by	
  
Sigma-‐Aldrich.	
  	
  Methoxy-‐poly(ethylene	
  glycol)	
  was	
  supplied	
  by	
  JenKem	
  Technology	
  
USA	
  (M-‐PEG-‐OH,	
  Mw	
  5000).	
  	
  
	
  

Acetonitrile	
  (C2H3N,	
  99.9%)	
  was	
  supplied	
  by	
  Fisher	
  Scientific.	
  PrestoBlue	
  Cell	
  

Viability	
  Reagent	
  and	
  Alexa	
  Fluor	
  647	
  cadaverine,	
  were	
  supplied	
  by	
  Life	
  
Technologies.	
  	
  For	
  the	
  filtration	
  of	
  the	
  nanoparticles,	
  Molecular	
  weight	
  cutoff	
  
centrifugal	
  filter	
  units	
  were	
  purchased	
  from	
  Millipore.	
  	
  Temozolomide	
  was	
  provided	
  
by	
  Molekula	
  and	
  O6-‐Benzylguanine	
  was	
  provided	
  by	
  Abcam	
  Technologies.	
  96-‐well	
  
plates,	
  T-‐75	
  and	
  T-‐25	
  flasks	
  were	
  supplied	
  by	
  GBO.	
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4.3	
  Statistical	
  Analysis	
  
All	
  statistical	
  analysis	
  was	
  performed	
  using	
  a	
  two-‐tailed	
  t-‐test	
  with	
  at	
  least	
  
five	
  repeats	
  each.	
  	
  Statistical	
  significance	
  was	
  set	
  at	
  p	
  <	
  0.05.	
  	
  Error	
  bars	
  on	
  graphs	
  
represent	
  the	
  standard	
  deviation	
  from	
  the	
  mean.	
  
4.4.	
  Experiment	
  Methods	
  
4.4.1.	
  Cell	
  Culture	
  
Daoy neuroblastoma cells (American Type Culture Collection, ATCC), D283
neuroblastoma cells (ATCC), SMS-KCNR neuroblastoma cells (ATCC), and SK-NBE(2) neuroblastoma cells (ATCC) were used for studies. All cells were of human origin
and were grown in monolayer cultures at 37°C at 5% of CO2. Daoy and D283
neuroblastoma cells were cultured using Eagle’s Minimum Essential Media (ATCC)
supplemented with 10% fetal bovine serum (Atlanta Biologics) and 1% penicillinstreptomycin amphotericin (MediaTech, Inc.) SMS-KCNR cells were cultured using
RPMI-1640 Media (ATCC) supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin-amphotericin. SK-N-BE(2) cells were cultured using EMEM/F12K Media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycinamphotericin. Cells were passaged and maintained in 75 cm2 flasks.
4.4.2. Nanoparticle Synthesis & Characterization
Poly(lactide)-poly(ethylene glycol) block copolymers were synthesized with ringopening polymerization. D,L lactide (17.4 mmol) and methoxy-poly(ethylene glycol)hydroxyl (0.133 mmol) were placed in a round-bottom flask with sodium sulfate (2.19
mmol) and dried overnight under vacuum (32 in Hg). Reaction components were
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dissolved in 10 mL anhydrous toluene at 120°C purged under N2. Stannous octoate
(0.016 mmol) was added to the solution, purged under N2. The solution was stirred for
12 hours. Next, the reaction vessel was removed from heat and allowed to come to room
temperature. The reaction product was washed with chloroform and water in a separation
funnel and the bottom phase of the product was collected. Product was dried with
magnesium sulfate, filtered, and concentrated using a rotary evaporator. Polymer was
then precipitated in cold (-80°C) methanol overnight. Product was collected via
centrifugation and lyophilization. Polymers were characterized with nuclear magnetic
resonance spectroscopy (Bruker 300 MHz).
Polymeric nanoparticles (NP) were formed using a solvent evaporation technique.
PLA-PEG-OCH3 block copolymer was dissolved in acetonitrile at 5 mg/mL. NPs were
synthesized by mixing the polymer solution at a 1:2 ratio in water and stirring for 2
hours. Solutions were collected and washed in 100 kD nominal molecular weight limit
(NMWL) centrifugal filter units (3,500 rpm, 7 minutes) twice with water and once with
phosphate buffered saline (PBS). NPs were re-suspended in cell culture media at the
desired concentration per application.
To synthesize O6-BG loaded NPS used for drug delivery studies; O6-BG was
dissolved in acetonitrile at 2 mg/mL. Then, PLA-PEG was dissolved in the O6-BG
containing acetonitrile at 5 mg/mL and allowed to mix on a rotisserie for 1 hour.
Nanoparticles were prepared from this solution using the same solvent evaporation
technique described previously.
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To synthesize fluorescently labeled NPs used in cellular uptake studies, PLA
polymer was conjugated with AlexaFluor 647 cadaverine using EDC chemistry. PLA
was dissolved in anhydrous dimethylformamide (DMF) and mixed with 10-fold excess
EDC. Solution was vortexed and 10-fold excess of AlexaFluor 647 cadaverine was
added to the PLA and stirred overnight. This solution was concentrated with the rotary
evaporator, re-dissolved in chloroform, precipitated in cold methanol (-80°C), and
collected via lyophilization. The final PLA-AF647 polymer was mixed with PLA-PEG
in acetonitrile at a 6:4 (PLA-PEG:PLA-647) ratio and NPs were formed using the same
solvent evaporation technique described previously.
4.4.3. Free Drug Toxicity for Drug Delivery
To analyze in vitro toxicity, D283, Daoy, SK-N-BE(2) and SMS-KCNR
neuroblastoma cells were seeded in wells of a black, clear bottom, cell bind 96-well plate
at a density of 50,000 cells/well in 200 microliters of cell media. Plates were incubated
overnight at 37°C and 5% CO2 to allow the cells to adhere.
To test free TMZ toxicity, the following day, 1 milligram of TMZ was weighed
out and dissolved in 1 milliliter of cell media. Solutions were made at concentrations of
250, 400, 600, 800 and 1000 microgram TMZ/milliliter cell media in a sterile hood.
Then, 200 microliters of each drug concentration was added to each of 5 wells with
neuroblastoma cells; a control column containing 5 wells of only cell media was also
added. 3 well plates were prepared for incubation periods of 24, 48 and 72-hours at 37°C
and 5% CO2. After each respective incubation period, the drug solutions were removed
from each well and replaced with 200 microliters of fresh media. After the final
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incubation of 72-hours, the cell media was removed and 200 microliters of a 10:1
solution of cell media to Presto Blue Cell Viability Reagent was added to each well. The
well plate was then incubated at 37°C and 5% CO2 for 40 minutes covered from light.
The fluorescence signal was then read using a Biotek Synergy 4 fluorescent plate reader
with Gen5 1.11 software with an excitation wavelength of 560 nanometers and an
emission wavelength of 590 nanometers. The data was then analyzed by comparing the
average fluorescent intensity of the samples with 0 microgram/milliliter drug
concentration (control) as 100% viability to the average intensity of samples incubated
with the various drug concentrations.
To test free O6-BG toxicity, the day after seeding 96-well plates with cells, 1
milligram of O6-Benzylguanine was weighed out and dissolved in 100 microliters of
Dimethyl Sulfoxide and 1 mL of cell media. Solutions were made at concentrations of 0,
3.125, 6.25, 12.5 and 50 microgram O6-BG/milliliter of cell media in a sterile hood.
Then, 200 microliters of each drug concentration was added to each of 5 wells with
neuroblastoma cells; a control column containing 5 wells of only cell media was also
added. 3 well plates were prepared for incubation periods of 24, 48 and 72-hours at 37°C
and 5% CO2. After each respective incubation period, the drug solutions were removed
from each well and replaced with 200 microliters of fresh media. After the final
incubation of 72-hours, the cell media was removed and 200 microliters of a 10:1
solution of cell media to Presto Blue Cell Viability Reagent was added to each well. The
well plate was then incubated at 37°C and 5% CO2 for 40 minutes covered from light.
The fluorescence signal was then read using a Biotek Synergy 4 fluorescent plate reader
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with Gen5 1.11 software with an excitation wavelength of 560 nanometers and an
emission wavelength of 590 nanometers. The data was then analyzed by comparing the
average fluorescent intensity of the samples with 0 microgram/milliliter drug
concentration (control) as 100% viability to the average intensity of samples incubated
with the various drug concentrations.
To test the toxicity of the two drugs in combination, 3 different combination
studies were conducted. First, TMZ concentrations were held constant at 128uM and
256uM and O6-BG was varied at 10, 20, 30 and 64uM; second, O6-BG concentrations
were held constant determined by the results of the free O6-BG study, while TMZ was
varied at 250, 400, 600, 800 and 1000 microgram TMZ/milliliter cell media. To carry
out these experiments, cells were seeded in 96-well plates as described previously. The
next day, the drugs were weighed out and solutions of the different concentrations were
prepared as described previously. Then, 100 microliters of the TMZ solution and 100
microliters of the O6-BG solution were added to 5 wells of each concentration. A control
column of 5 wells containing only cell media and a column of 5 wells containing only the
drug administered at constant concentration was also added. 3 well plates were prepared
for incubation periods of 24, 48 and 72 hours at 37°C and 5% CO2. After each respective
incubation period, the drug solutions were removed from each well and replaced with 200
microliters of fresh media. After the final incubation of 72-hours, the cell media was
removed and 200 microliters of a 10:1 solution of cell media to Presto Blue Cell Viability
Reagent was added to each well. The well plate was then incubated at 37°C and 5% CO2
for 40 minutes covered from light. The fluorescence signal was then read using a Biotek
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Synergy 4 fluorescent plate reader with Gen5 1.11 software with an excitation
wavelength of 560 nanometers and an emission wavelength of 590 nanometers. The data
was then analyzed by comparing the average fluorescent intensity of the samples with 0
microgram/milliliter drug concentration (control) as 100% viability to the average
intensity of samples incubated with the various drug concentrations.
4.4.4. O6-BG Loaded NP & Unloaded NP Toxicity for Drug Delivery
To confirm that O6-BG and the PLA-PEG-(OCH3) NP were non-toxic to the
neuroblastoma cells, the cells were treated with NP loaded with O6-BG and unloaded NP.
The neuroblastoma cells were seeded in 30 wells of black, clear bottom, cell bind 96-well
plates at a density of 50,000 cells/well in 200 microliters of cell media. Plates were then
incubated overnight at 37C and 5% CO2 to allow the cells to adhere. The next day, O6BG was encapsulated in NPs using the same solvent evaporation and washing methods
described previously, and unloaded NP were prepared the same way. The nanoparticle
solutions were prepared at 0.1, 0.5, 1, 2.5, and 5 milligram mPLA-PEG/milliliter cell
media in a sterile hood. Then, 200 microliters of each nanoparticle concentration was
added to each of 5 wells with neuroblastoma cells. A control column was also added
with 5 wells containing only cell media. Plates were prepared based on loaded NP
treatment and unloaded NP treatment. 4 plates of each treatment type were made for
incubation periods of 12, 24, 48, and 72-hours. The well plates were then incubated at
37C and 5% CO2. After each incubation period, the cell media containing nanoparticles
was removed and 200 microliters of fresh media was added to each well. After the final
incubation, the cell media was removed and 200 microliters of a 10:1 solution of cell
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media to Presto Blue Cell Viability Reagent was added to each well. The well plate was
then incubated at 37C and 5% CO2 for 40 minutes covered from light. Then, the
fluorescence signal was read using a 48Biotek Synergy 4 fluorescent plate reader with
Gen5 1.11 software with an excitation wavelength of 560 nanometers and an emission
wavelength of 590 nanometers. The data was then analyzed by comparing the average
fluorescent intensity of the samples with 0 milligram/milliliter nanoparticle concentration
as 100% viability to the average intensity of samples incubated with nanoparticles.
4.4.5. Toxicity of O6-BG Loaded NP & Free TMZ
To test the effect of combination treatment with O6-BG loaded NP (NPO6) and
free TMZ on neuroblastoma cell viability, neuroblastoma cells were seeded in 30 wells of
a black, clear bottom, cell bind 96-well plate at a density of 50,000 cells/well in 200
microliters of cell media. Plates were incubated at 37C and 5% CO2 to allow the cells to
adhere. The next day, NPO6 were synthesized using the same encapsulation and solvent
evaporation method described previously. Concentration of NP used was the ideal nontoxic concentration determined by the O6-BG loaded NP studies and O6-BG
concentration was prepared at 2 mg/mL. 1 milligram of TMZ was weighed out and
solutions were made at concentrations of 100, 250, 400, and 600 microgram
TMZ/milliliter cell media.

Then, 100 microliters of the NPO6 solution and 100

microliters of the TMZ solution was added to each of 5 wells per concentration of TMZ.
A control column of 5 wells containing only media, and a column containing 5 wells of
only NPO6 was also added. After 72 hours, the cell media containing nanoparticles was
removed and 200 microliters of a 10:1 solution of cell media to Presto Blue Cell Viability
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Reagent was added to each well. The well plate was then incubated at 37C and 5% CO2
for 40 minutes covered from light. The fluorescence signal was then read using a Biotek
Synergy 4 fluorescent plate reader with Gen5 1.11 software with an excitation
wavelength of 560 nanometers and emission wavelength of 590 nanometers. The data
was then analyzed by comparing the average fluorescent intensity of the samples with 0
microgram/milliliter nanoparticle concentration as 100% viability to the average intensity
of samples incubated with TMZ and NPO6.
4.4.6 Quantification of Nanoparticle Uptake into Cells
To analyze nanoparticle uptake into cells, neuroblastoma cells were seeded in 25
wells of a black, clear bottom, cell bind 96-well plate at a density of 50,000 cells/well in
200 microliters of cell media. Plates were incubated at 37C and 5% of CO2 to allow cells
to adhere. The next day, AlexaFluor 647 Fluorescently-labeled NPs were synthesized
using the method described previously. Then, 200 microliters of the NP at 2
milligrams/milliliter of cell media were added to the wells. 5 columns of 5 wells each
were made on the well plate; 1 control column containing only cell media, and the
remaining 4 columns for 4 different incubation periods: 1 hour, 24 hours, 48 hours and 72
hours. After each incubation, NP-containing media was removed and wells were gently
washed three-times with sterile PBS. Next, wells were trypsinized, collected via
centrifugation, and resuspended in 200 µL sterile PBS. Samples were then transferred to
a new 96-well plate, with fluorescent measurements (Ex/Em 645/680) recorded for each
sample.
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4.5. Experiment Results and Discussion
4.5.1. Synthesis of PLA-PEG-(OCH3)
Synthesis of PLA-PEG-(OCH3) polymeric nanoparticles was successful in
yielding biocompatible particles for the use in drug delivery applications. Figure 3 shows
the particle size profiles of the nanoparticles while Figure 4 shows the particle size
profiles of the O6-BG loaded nanoparticles. To describe the basic nanoparticle structure,
PLA is generally hydrophobic and therefore forms the core of the spherical nanoparticle,
while the hydrophilic PEG forms the protective outer shell.

Figure 3 | Particle size distribution of PLA-PEG(OCH3) nanoparticles. Acquired
using BIC Particle Size Software.
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Figure 4 | Particle size distribution of O6-BG loaded PLA-PEG(OCH3) NP. Acquired
using BIC Particle Size Software.
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4.5.2. Western Blot Data
Figure 5 below displays the relative amounts of MGMT expression in various
neuroblastoma tumor cells. It is important to examine this data to determine the varying
MGMT levels in each cell line tested, and to be able to compare which cell lines express
the most and the least MGMT. This allows for determination of which cell lines would
be expected to show the most and least amount of drug resistance. Figure 6 quantifies the
western blot images into relative values of expression. To do this, MGMT to ß-actin
ratio was calculated and the values were normalized to DAOY, since it had the lowest
MGMT:ß-actin value.

Figure 5 | Western Blot Results showing protein expression in various
neuroblastoma and brain tumor cell lines. Credit: Dr. Jacqueline Kraveka,
MUSC
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Figure 6 | Graph of MGMT protein expression in each cell line. Values are
normalized to β-actin protein.

4.5.3. O6-BG Toxicity
Toxicity studies were performed to determine the interaction the drug O6-BG
would have with a neuroblastoma cell. This was conducted on the 4 cell lines, Daoy, D283, SK-N-BE(2), and SMS-KCNR. The results of this study were used to determine the
concentration of O6-BG to be used in TMZ+O6 combination studies. These studies
showed minimal toxicity in the cells, since O6-BG is a non-toxic drug. 80% viability was
viewed as an acceptable toxicity level for the purposes of this study.
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The viability of D-283 cells remained around 80% even at higher drug
concentrations such as 256 µM up to 24 hours incubation, but progressively declined to
around 60% as incubation time increased to 72 hours. For this cell line, 64 µM was
determined as the concentration of O6-BG to be used for the drug combination studies.

Figure 7 | Toxicity of O6-BG in D-283 Cells. Cell viability around 80% for
elevated drug concentration indicates an acceptable toxicity
In Daoy cells, viability remained around 75-80% even as drug concentration was
elevated to 256uM and incubation period was increased to 72 hours. For this cell line,
128 µM was determined as the O6-BG concentration to be used in the drug combination
studies.
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Figure 8 | Toxicity of O6-BG in Daoy Cells. Cell viability around 80% for
elevated drug concentration indicates an acceptable toxicity.
In SK-N-BE(2) cells, there was more variability in cell viability. Viability
remained above 80% up to 24 hours at concentrations up to 128 µM, dropped
significantly at 48 hours down to almost 40% at 256 µM. At 72 hours, however, viability
remained well above 80% up to 256 µM. For this cell line, 64 µM was determined to be
the concentration of O6-BG used in the drug combination studies.
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Figure 9 | Toxicity of O6-BG in SK-N-BE(2) Cells. Cell viability around 80%
for elevated drug concentration indicates an acceptable toxicity.
In SMS-KCNR cells, viability remained around or above 80% until 24 hours up to
128 µM, however slightly dropped after 48 and 72 hours to 65-70% viability and
decreased to around 60% at the highest conentration of 256 µM. For this cell line, 64 µM
was determined to be the concentration of O6-BG used in the drug combination studies.
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Figure 10 | Toxicity of O6-BG in SMS-KCNR Cells. Cell viability around 80%
for elevated drug concentration indicates an acceptable toxicity.
4.5.4. Nanoparticle Toxicity
Toxicity studies were performed to determine the interaction the PLA-PEG(OCH3) particles and the O6-BG loaded PLA-PEG-(OCH3) particles would have with the
neuroblastoma cells. These studies showed minimal toxicity in the cells. For the
purposes of this study, 80% viability was considered to be an acceptable toxicity level.
The results of this study were used to determine what concentration of nanoparticles
should be used for the NPO6+TMZ combination drug studies.
In D-283 cells, there was no toxicity associated with either the unloaded
nanoparticles or the drug-loaded nanoparticles. Cell viability remained close to 100% up
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to the highest concentration of 5 mg/mL. For this cell line, 5 mg/mL was determined to
be the concentration of nanoparticles used in NPO6+TMZ combination drug studies.

Figure 11 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in
D-283 Cells. Cell viability around 80% for elevated nanoparticle concentration
indicates an acceptable toxicity.
In Daoy cells, there was no toxicity associated with either the unloaded NP or the
drug-loaded NP. Cell viability remained close to 100% up to 2.5 mg/ml and declined to
around 70% at 5 mg/ml concentration. For this cell line, 2.5 mg/ml was determined to be
the concentration used in the NPO6+TMZ drug combination studies.
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Figure 12 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in
Daoy Cells. Cell viability around 80% for elevated nanoparticle concentration
indicates an acceptable toxicity.
SK-N-BE(2) cells also exhibited no toxicity as a result of both nanoparticle
treatments. Viability remained close to 100% for all concentrations and nanoparticle
treatments. Only at 1 mg/ml did the cell viability decrease to around 80% with the drugloaded nanoparticles. For this cell line, 5 mg/ml was determined to be the concentration
used for the NPO6+TMZ drug combination studies.
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Figure 13 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in
SK-N-BE(2) Cells. Cell viability around 80% for elevated nanoparticle
concentration indicates an acceptable toxicity
In SMS-KCNR cells, there was no toxicity associated with the unloaded
nanoparticle treatment and minimal toxicity associated with the loaded-nanoparticle
treatment. Cell viability in the loaded-nanoparticle remained around 100% up to 1
mg/ml, and decreased to 80% and 70% at 2.5 and 5 mg/ml, respectively. For this cell
line, 2.5 mg/ml was determined to be the concentration used for the NPO6+TMZ drug
combination studies.
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Figure 14 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in
SMS-KCNR Cells. Cell viability around 80% for elevated nanoparticle
concentration indicates an acceptable toxicity.
4.5.5. TMZ Toxicity
Toxicity studies were performed to determine the interaction the drug
Temozolomide (TMZ) would have with a neuroblastoma cell. This was conducted on the
4 cell lines, Daoy, D-283, SK-N-BE(2), and SMS-KCNR. The results of this study were
used to determine the highest concentration of TMZ that could be administered without
causing toxicity to normal cells. TMZ is a toxic drug, so a higher level of toxicity was
expected. Viability above 40% was viewed as an acceptable toxicity level for the
purposes of this study.
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In D-283 cells, viability decreased steadily with increasing TMZ concentration.
At these concentrations, it is clear that TMZ had a fairly toxic effect on the cells,
especially at 800 and 1000 µg/ml, cell viability remained below 40%, which would likely
affect normal cells as well. Cell viability remained above 40% for 250 and 600 µg/ml.
Based on this study, TMZ concentrations up to 600 µg/ml were determined to be used for
the NPO6+TMZ drug combination studies.

Figure 15 | Toxicity of TMZ in D-283 Cells. Cell viability above 40% for
elevated TMZ concentration indicates an acceptable toxicity.
In Daoy cells, there was a dramatic decrease in cell viability with increasing TMZ
concentration. Viability remained above 40% for 250 and 400 µg/ml incubation. Post
this point, viability dropped below 40% for all higher concentrations up to 1000 µg/ml.
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Based on this study, TMZ concentrations up to 600 µg/ml were determined to be the
concentrations used for the NPO6+TMZ drug combination studies.

Figure 16 | Toxicity of TMZ in Daoy Cells. Cell viability above 40% for
elevated TMZ concentration indicates an acceptable toxicity.
In SK-N-BE(2) cells, viability remained close to 40% up to 400 µg/ml and
dropped below 40% from 600-1000 µg/ml. Based on this study, TMZ concentrations of
up to 600 µg/ml were used for the NPO6+TMZ drug combination studies.
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Figure 17 | Toxicity of TMZ in SK-N-BE(2) Cells. Cell viability above 40% for
elevated TMZ concentration indicates an acceptable toxicity.
In SMS-KCNR cells, there was a high level of toxicity associated with TMZ.
Cell viability remained below 50% for all concentrations of TMZ, and dropped below
40% at 400 µg/ml up to 1000 µg/ml. Based on this study, TMZ concentrations up to 600
µg/ml were used for the NPO6+TMZ drug combination studies.
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Figure 18 | Toxicity of TMZ in SMS-KCNR Cells. Cell viability above 40% for
elevated TMZ concentration indicates an acceptable toxicity.
4.5.6. Free Drug Combination Toxicity
Toxicity studies were performed to determine the interaction both drugs, O6-BG
and TMZ, in combination would have on a neuroblastoma cell. This test was conducted
on the 4 cell lines, D-283, Daoy, SK-N-BE(2), and SMS-KCNR. The results of this study
were used to determine the effect O6-BG would have on enhancing TMZ toxicity, as
hypothesized. These studies showed a high level of toxicity, as TMZ concentration
increased with a constant concentration O6-BG. Cell viability above 40% was viewed as
an acceptable toxicity level for the purposes of this study.
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In D-283 cells, there was a high level of toxicity as TMZ concentration increased
from 250 µg/ml to 1000 µg/ml. Viability remained 40-60% up to 400 µg/ml and dropped
below 40% at 600 µg/ml up to 1000 µg/ml. O6-BG concentration was held constant at 64
µM which was determined by the results of the free O6-BG toxicity studies. It was also
determined that the concentration of TMZ administered would not exceed 600 µg/ml for
the NPO6+TMZ studies.

Figure 19 | Toxicity of O6-BG & TMZ in D-283 Cells. Cell viability above
40% for elevated TMZ concentration indicates an acceptable toxicity.
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Figure 20 shows the results of administering 128 µM O6-BG with increasing
concentrations of TMZ after 72 hours incubation. The combination of TMZ and O6-BG
resulted in a high level of toxicity, with cell viability remaining below 40% at
concentrations above 250 µg/ml. Based on this study, it was determined that TMZ
concentrations up to 600 µg/ml would be used for the NPO6+TMZ drug combination
studies.

Figure 20 | Toxicity of O6-BG & TMZ in Daoy Cells at 72H. Cell viability
above 40% for elevated TMZ concentration indicates an acceptable toxicity level.
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In SK-N-BE(2) cells, viability was high, around 70%, at TMZ concentration of
250 µg/ml and 64 µM O6-BG. At 400 µg/ml TMZ, viability dropped below 40% and
continued to decline up to 1000 µg/ml. For this cell line, it was determined that TMZ
concentrations up to 600 µg/ml would be used for the NPO6+TMZ drug combination
studies.

Figure 21 | Toxicity of O6-BG & TMZ in SK-N-BE(2) Cells at 72H. Cell
viability above 40% for elevated TMZ concentration indicates an acceptable
toxicity level.
In SMS-KCNR cells, cell viability remained above 40% up to 400 µg/ml TMZ,
and dropped below 40% at 600 µg/ml up to 1000 µg/ml after 24 hours incubation. After
48 hours incubation, cell viability dropped below 40% at 400 µg/ml and at 250 µg/ml
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after 72 hours incubation. For this cell line, it was determined that TMZ concentrations
up to 600 µg/ml would be used for the NPO6+TMZ drug combination studies.

Figure 22 | Toxicity of O6-BG & TMZ in SMS-KCNR Cells. Cell viability
above 40% for elevated TMZ concentration indicates an acceptable toxicity level.
4.5.7. O6-BG Loaded Nanoparticles with TMZ Toxicity
Toxicity studies were performed to determine the interaction of combining
nanoparticles loaded with O6-BG and free TMZ with neuroblastoma cells. These tests
were conducted on the 4 cell lines, D-283, Daoy, SK-N-BE(2), and SMS-KCNR. O6-BG
was loaded at 2 milligrams/milliliter concentration in the nanoparticles and administered
with varying TMZ concentrations from 100 to 600 µg/ml. It was expected to observe a
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significant level of toxicity, indicating that this combination therapy would enhance the
efficacy of TMZ as a therapeutic through the aid of the MGMT-inhibiting properties of
O6-BG. A toxicity level greater that 40% (less than 60% cell viability) was viewed as an
acceptable level for the purposes of this study.
In D-283 cells, there was a moderate level of toxicity associated with the
combination NPO6/TMZ treatment. There was minimal toxicity resulting from the
NPO6 alone, and cell viability steadily declined as TMZ concentration increased.
Viability did not drop below 20% for any concentration of TMZ.

Figure 23 | Toxicity of O6-BG loaded nanoparticles & TMZ in D-283 cells.
Cell viability below 60% indicates an acceptable toxicity level.
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In Daoy cells, there was some toxicity observed. Viability remained around 60%
for all concentrations of TMZ, while minimal toxicity was associated with only NPO6.
At 100 µg/ml TMZ, there was also no toxicity observed, however, at 250 µg/ml, a steady
decline in cell viability can be observed up to 600 µg/ml. Overall, the effect of this
treatment on this cell line can be identified as ‘moderate’.

Figure 24 | Toxicity of O6-BG loaded nanoparticles & TMZ in Daoy cells.
Cell viability below 60% indicates an acceptable toxicity level.
In SK-N-BE(2) cells, viability remained around 60% up to 250 µg/ml and
dropped below 60% at 400 µg/ml, decreasing to around 40% at 600 µg/ml. There was
also a slight toxic effect on the cells by the NPO6 alone.
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Figure 25 | Toxicity of O6-BG loaded nanoparticles & TMZ in SK-N-BE(2) cells.
Cell viability below 60% indicates an acceptable toxicity level.
In SMS-KCNR cells, there was a significant level of toxicity associated with the
combination NPO6+TMZ treatment. Cell viability remained around 60% from 100 to
250 µg/ml, and dropped below 60% at 400 µg/ml. Viability decreased dramatically to
about 25% at 600 µg/mL TMZ concentration.
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Figure 26 | Toxicity of O6-BG loaded nanoparticles & TMZ in SMS-KCNR
cells. Cell viability below 60% indicates an acceptable toxicity level.
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4.5.8. Combined Toxicity Data
The figures below show combined results of toxicity for each cell line. The
graphs display cell viability at incubation periods varied from 24 to 72 hours from a
series of free drug experiments as well as combination drug studies with free drug and
nanoparticles loaded with O6-BG. The figures display the results of the following
treatments: 128 µM TMZ, 256 µM TMZ, 64/128 µM O6-BG, 128 µM TMZ + 64/128 µM
O6-BG, and 256 µM TMZ+64/128 µM O6-BG. Then, 600 µg/ml TMZ, 600 µg/ml
TMZ+ 64/128 µM O6-BG, and 600 µM TMZ+ NPO6, with O6-BG loading at 2 mg/ml in
the nanoparticles. The figures give a comprehensive view of the overall effect of each
treatment on cell viability, and allow for analysis to determine whether the combination
NPO6+TMZ treatment is indeed an effective method of treating neuroblastomas.

Figure 27 | Cell viability of 5 free drug toxicity tests on D-283 cells.
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Figure 28 | Cell viability of 5 free drug toxicity tests on Daoy cells.

Figure 29 | Cell viability of 5 free drug toxicity tests on SK-N-BE(2) cells.
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Figure 30 | Cell viability of 5 free drug toxicity tests on SMS-KCNR cells.

Figure 31 | Cell viability of 3 drug combination toxicity tests on D-283 cells.
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Figure 32 | Cell viability of 3 drug combination toxicity tests on Daoy cells.

Figure 33 | Cell viability of 3 drug combination toxicity tests on SK-N-BE(2)
cells.
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Figure 34 | Cell viability of 3 drug combination toxicity tests on SMS-KCNR
cells.

4.5.8 Nanoparticle Uptake
Fluorescent nanoparticles were formulated to confirm that the nanoparticles were
indeed uptaken into the cells. This study was carried out for 72 hours, with individual
time points taken at 1 hour, 24 hours, 48 hours, and 72 hours. NP uptake into cells varied
between cell lines, although all showed significant uptake after 24 hours. D-283 cells
showed significant level of uptake after 24 hours, about 8-fold increase from 1 hour
incubation.
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Figure 35 | NP Uptake into D-283 cells.
Daoy cells also successfully demonstrated cellular uptake up to 24 hours. There was
about a 2.6 fold increase from 1 hour to 24 hours.

Figure 36 | NP Uptake into Daoy Cells.
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SK-N-BE(2) cells showed an improved uptake level compared to D-283 and Daoy cells.
There was a significant level of uptake up to 48 hours of incubation. Uptake levels
increased 3.4 fold from 1 hour to 24 hours, and almost 4 fold from 24 hours to 48 hours,
totaling more than 12 fold increase in uptake from 1 hour to 48 hours of incubation.

Figure 37 | NP Uptake into SK-N-BE(2) Cells.
SMS-KCNR cells showed increasing levels of uptake up to 72 hours, and it was the only
cell line to do so. There was approximately 2.6 fold increase in uptake from 1 hour to 72
hours.
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Figure 38 | NP uptake into SMS-KCNR Cells.
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4.6. Conclusion of Results
The synthesis of PLA-PEG-(OCH3) nanoparticles for the purpose of
encapsulating and delivering drugs with controlled pharmacokinetics was achieved. Not
only was the biocompatibility and non-toxicity of the nanoparticles demonstrated, but
also the uptake of the nanoparticles into cells observed. This, along with the confirmed
non-toxic properties of the MGMT-inhibitor O6-BG, allows for an effective combination
treatment with TMZ to enhance the toxicity and effectiveness of the drug in eliminating
neuroblastoma cells. The results of the free TMZ studies showed that the drug is toxic to
the cells, however, the effect of the drug resulted in very high toxicity levels indicating
that the elevated concentrations administered are likely to be toxic to normal cells and
tissues. The results of the free drug combination delivery of O6-BG + TMZ also showed
high toxicity levels, more enhanced in the cases of D-283, SK-N-BE(2), and SMS-KCNR
cells than the free TMZ studies. However, once again the toxicity levels appeared
extremely high which indicates that this treatment may be toxic to normal cells and
tissues. The combination drug delivery of O6-BG loaded nanoparticles (NPO6) with
TMZ showed improved toxicity, however was lower compared to the free drug
treatments. This can be explained by the fact that the drug loading in the NPO6+TMZ
experiments was much lower than the free drug studies. The results show promise for a
potential therapeutic system for the combination drug delivery using these nanoparticles.
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CHAPTER 5
CONCLUSIONS
The 5-year survival rate for high-risk neuroblastoma is only 15%, which is
evidence enough that the development of an effective treatment is extremely important.
Presently, there are many treatment options that can treat the cancer, but not without side
effects and the most challenging problem of drug resistance. Therefore, more focus must
be placed on finding treatments that are more direct and target the tumor itself while
avoiding normal cells. Nanoparticles are promising tools for delivering drugs due to their
biocompatibility, ability to passively or directly target tumors, and controlled release of
drugs to allow for lower dosage. These properties can effectively reduce side effects and
systemic toxicity. Temozolomide is a commonly used therapeutic to treat neuroblastoma,
but is inhibited from carrying out it’s full function due to drug resistance induced by
MGMT present in the cells. The co-administration of O6-Benzylguanine with TMZ has
the potential to be an effective method due to its ability to inhibit MGMT activity thereby
allowing TMZ to fulfill its role in reducing the neuroblastoma cell viability. The results
show that the encapsulation of O6-BG into the PLA-PEG(OCH3) nanoparticles was
successful and co-administration with TMZ demonstrated a significant decrease in
neuroblastoma cell viability without causing extreme levels of toxicity which could affect
normal cells..
Overall, this combination drug nanoparticle delivery system shows strong
potential for further development as a mechanism for the effective treatment of high-risk
neuroblastoma.
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CHAPTER 6
RECOMMENDATIONS FOR FUTURE RESEARCH
1. Attachment of targeting ligands such as peptides to the nanoparticles to target
EGFR.
2. Analysis of drug loaded and unloaded nanoparticle uptake into 3D spheroid
models, as well as toxicity studies in cell spheroids.
3. In vivo animal studies of drug loaded nanoparticles to examine uptake, drug
release and biocompatibility.
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